Trxade Group (MEDS) has issued an announcement.
On July 25, 2024, TRxADE HEALTH, INC. finalized a merger with Scienture, Inc., wherein Scienture became a wholly owned subsidiary and subsequently merged with the Company’s subsidiaries, leading to a rebranding as Scienture Holdings, Inc. This strategic move aims to leverage Scienture’s expertise in pharmaceutical research and its portfolio of innovative products targeting unmet medical needs. Shareholders of Scienture received a mix of common and preferred shares in the newly formed entity, with the preferred shares set to convert under certain conditions, enhancing value and potential growth for investors.
For a thorough assessment of MEDS stock, go to TipRanks’ Stock Analysis page.
